Takeda Pharmaceutical says it is considering making an approach to Shire regarding a possible offer for the company. Under UK takeover rules, Takeda has until April 25, 2018 to announce its firm intention to make an offer or not. Read More

GlaxoSmithKline (GSK) has agreed to buy Novartis’ 36.5% stake in the companies’ consumer healthcare joint venture for $13 billion that would provide GSK full ownership of the business. GSK and Novartis formed the joint venture in 2015. Read More

AbbVie reports the global resolution of all intellectual property-related litigation with Samsung Bioepis, a joint venture between Samsung BioLogics, a contract biologics manufacturer, and Biogen, over Samsung Bioepis’ proposed biosimilar of AbbVie’s Humira (adalimumab), its top-selling drug with 2017 global sales of $18.43 billion. Read More

Eli Lilly and Company and Sigilon Therapeutics, a cell-therapy company, have formed a global collaboration to develop encapsulated cell therapies for the potential treatment of Type 1 diabetes in a deal worth up to $473 million ($63 million upfront and $410 million in milestones). Read More

Celgene announced on April 2, 2018 that Scott A. Smith, President and Chief Operating Officer is leaving the company, effective immediately. His primary responsibilities will be assumed by Chairman and Chief Executive Officer Mark J. Alles. Read More

Fujifilm has agreed to acquire Santa Ana, California-based Irvine Scientific Sales Company and Tokyo, Japan-based IS Japan, which provide cell-culture media for biopharmaceutical production,  in vitro  fertilization, and cell therapies, for approximately $800 million. Read More

Corning plans to build a new high-volume pharmaceutical glass packaging manufacturing facility in Durham County, North Carolina to support production of Corning Valor Glass, a new parenteral drug packaging product. The facility is part of a first-phase investment of $500 million to support development and manufacturing of the product.  Read More

Eisai and Nichi-Iko Pharmaceutical have formed a capital and business alliance and share-transfer agreement relating to their generic-drug businesses, which includes Eisai’s generics subsidiary, Elmed Eisai ,  and collaboration on Eisai’s active pharmaceutical ingredient business. Read More

Pfizer and Allogene Therapeutics have signed an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR-T) therapies. Allogeneic therapies are developed from cells of healthy donors and stored for “off-the-shelf” use in patients. Read More

At the DCAT Member Company Announcement Forum held during DCAT Week ‘18, senior executives provided their companies’ latest key strategic developments, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions. Read More